Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5321 - Impact of liver tumor burden on therapeutic effect of 177Lu-Dotatate treatment in NETTER-1 study


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Tumour Site

Neuroendocrine Neoplasms


Jonathan Strosberg


Annals of Oncology (2018) 29 (suppl_8): viii467-viii478. 10.1093/annonc/mdy293


J. Strosberg1, A. Hendifar2, J.C. Yao3, M. Kulke4, T. O'Dorisio5, M. Caplin6, R.P. Baum7, P. Kunz8, T. Hobday9, E. Wolin10, E.S. Mittra11, K. Oberg12, P. Ruszniewski13, B. Polack14, B. He15, D. Barton14, P. Santaro14, E. Krenning16

Author affiliations

  • 1 Gi Oncology, H. Lee Moffitt Cancer Center University of South Florida, 33612 - Tampa/US
  • 2 Im/hematology/oncology, Cedars-Sinai Medical Center, 90048 - Los Angeles/US
  • 3 Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 4 Department Of Medical Oncology, Dana-Farber Cancer Institute, 2215 - Boston/US
  • 5 Gastrointestinal Neurocrine Mog, University of Iowa, IA 52242 - Iowa City/US
  • 6 Neuroendocrine Tumour Unit, Royal Free Hospital School of Medicine, NW3 2QG - London/GB
  • 7 Nuclear Medicine, Zentralklinik, Bad Berska/DE
  • 8 School Of Medicine, Stanford University, California/US
  • 9 Oncology, Mayo Clinic College of Medicine, Rochester/US
  • 10 Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York/US
  • 11 Diagnostic Radiology, Oregon Health and Science University, Portland/US
  • 12 University Hospital, Uppsala University, University Hospital, Uppsala/SE
  • 13 Gastroenterology, Hôpital Beaujon, 92110 - Clichy/FR
  • 14 Medical Affairs, Advanced Accelerator Applications, a Novartis company, New York/US
  • 15 Biometrics And Biostatistics, Advanced Accelerator Applications, a Novartis company, Geneva/CH
  • 16 Erasmus Medical Center, Rotterdam, 3015 - Rotterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5321


The aim of this study was to assess Progression Free Survival (PFS), Safety and Quality of Life (QoL) in subgroups of varying hepatic burden in the NETTER-1 study population.


Patients (pts) were randomized to receive either 177Lu-DOTATATE (Lu)(n = 117) or high-dose octreotide (Oct) (n = 114). The liver tumor burden (LTB) was defined as tumor volume/total liver volume by CT, and categorized as low (<25%), moderate (25-50%), and high (>50%). PFS, QoL and hepatotoxicity were assessed based on baseline LTB. QoL was analysed using EQRTC QLQC 30 and G.I. NET 21 questionnaires completed at baseline and every 12 weeks thereafter for low and moderate/high LTB subgroups. Deterioriation was defined if the score decreased by ≥ 10 points at any time point after baseline. Time to deterioration (TTD) was defined as the time from randomization to the first QoL deterioration.


Median PFS (months) in Lu vs Oct was 28.35 vs 11.04 in low (HR = 0.218, 95% CI 0.120 to 0.394); Not Reached (NR) vs 8.67 in moderate (HR = 0.202, 95% CI 0.077 to 0.525); 19.38 vs 5.52 in high LTB (HR = 0.193, 95% CI 0.079 to 0.474), respectively. Median TTD (months) for Global Health Status was 28.81 vs 6.11 in low (HR = 0.376, 95% CI 0.196 to 0.720); NR vs 5.98 in moderate/high LTB (HR = 0.453, 95% CI 0.178 to 1.152). In Lu arm, Grade 3/4 (CTCAE v 4.03) AST and ALT toxicities occurred in the low LTB in 2 and 3 patients, and in the high LTB group in 3 and 1 patients, respectively. Grade 3/4 hyperbilirubinemia occurred in one patient from the low LTB and one from the moderate LTB group. All liver function tests abnormalities were resolved without sequela. There were no high grade ALT, AST and Biliriubin toxicities in Oct arm.


177Lu-DOTATATE treatment demonstrated significant PFS improvement regardless of the extent of baseline liver tumor burden in patients with well-differentiated, metastatic midgut NET. Clinically significant liver function test abnormalities were rare, were not associated with high liver tumor burden, and resolved without sequela. The analysis shows that 177Lu-DOTATATE treatment also provides quality of life benefit regardless of baseline liver tumor burden.

Clinical trial identification


Legal entity responsible for the study

Advanced Accelerator Applications, a Novartis company.


Advanced Accelerator Applications, a Novartis company.

Editorial Acknowledgement


B. Polack, B. He, D. Barton, P. Santaro: Employment: Advanced Accelerator Applications. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.